In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) and Hallucinogen Users
Archives of General Psychiatry – June 06, 2011
Source: OpenAlex
Summary
Compellingly, MDMA (Ecstasy) use, not hallucinogen use, is associated with lasting changes in the brain's serotonin transporter system. This pharmacology indicates MDMA, a serotonin reuptake inhibitor, directly impacts presynaptic serotonin levels, distinct from 5-HT receptor agonist actions of many psychedelics. These insights provide crucial context for Forensic Toxicology and Drug Analysis and broader Psychedelics and Drug Studies, showing subcortical serotonin transporter receptor binding may recover after months of abstinence. This influences Neurotransmitter Receptor Influence on Behavior, though cortical psychology-relevant recovery was not observed.
Abstract
We found evidence that MDMA but not hallucinogen use is associated with changes in the cerebral presynaptic serotonergic transmitter system. Because hallucinogenic drugs primarily have serotonin(2A) receptor agonistic actions, we conclude that the negative association between MDMA use and cerebral SERT binding is mediated through a direct presynaptic MDMA effect rather than by the serotonin(2A) agonistic effects of MDMA. Our cross-sectional data suggest that subcortical, but not cortical, recovery of SERT binding might take place after several months of MDMA abstinence.